Ken Griffin Foghorn Therapeutics Inc. Transaction History
Citadel Advisors LLC
- $505 Billion
- Q3 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Foghorn Therapeutics Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 8,600 shares of FHTX stock, worth $67,424. This represents 0.0% of its overall portfolio holdings.
Number of Shares
8,600
Previous 5,900
45.76%
Holding current value
$67,424
Previous $33,000
142.42%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding FHTX
# of Institutions
80Shares Held
33.3MCall Options Held
8.7KPut Options Held
2.4K-
Flagship Pioneering Inc. Cambridge, MA12.7MShares$99.4 Million20.03% of portfolio
-
Bvf Inc San Francisco, CA5.3MShares$41.6 Million1.57% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.03MShares$23.7 Million0.52% of portfolio
-
Raymond James & Associates St Petersburg, FL2.3MShares$18 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.73MShares$13.6 Million0.0% of portfolio
About Foghorn Therapeutics Inc.
- Ticker FHTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,637,400
- Market Cap $326M
- Description
- Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-28...